Meta Information

ID:boswellia-serrata

Name:Boswellia Serrata

Schema Version:1.5

Alternate Names

• Indian Frankincense
• Salai Guggal

Active Compound

Boswellic Acids

Intervention Type

therapeutic_agent

Delivery

Route:

oral

Scope:

• systemic

Regulatory Status

• us:dietary_supplement
• eu:food_supplement

Indication

Focus:

symptom_management

Description:

Manages inflammatory conditions and associated pain, particularly in musculoskeletal and digestive systems.

Typical Protocol

• Commonly taken as 300-500 mg of standardized extract (e.g., 65% boswellic acids) orally, two to three times daily.
• Dosages may vary based on product formulation and specific inflammatory condition being addressed.

Expected Cost Mean

Low Cost:

15

High Cost:

40

Cost Type:

monthly

Description:

Monthly cost for a typical oral supplement; generally not covered by insurance.

Summary

Boswellia serrata is a resin extract primarily known for its anti-inflammatory properties, mediated through the inhibition of 5-lipoxygenase (5-LO), an enzyme involved in leukotriene synthesis. Chronic low-grade inflammation is a significant contributor to aging and many age-related diseases, making boswellia a candidate for indirectly supporting healthspan by mitigating this process. Its primary established use is in managing symptoms of inflammatory conditions like osteoarthritis.

Purpose

Reduces systemic inflammation, supports joint health, and may indirectly impact aging pathways.

Card Summary

Botanical extract inhibiting inflammatory pathways, primarily used for joint and gut health.

Drug Class

null

Drugs In Class

Empty Array

Impact

Score:

5.2

Justification:

Reduces chronic inflammation, a known contributor to age-related decline.

Evidence

Grade:

B

Score:

6.5

Justification:

Moderate human evidence for anti-inflammatory effects and joint benefits.

Safety

Score:

3.5

Justification:

Generally well-tolerated with minor gastrointestinal side effects possible.

Flags

• May interact with blood thinners, potentially increasing bleeding risk.
• Can interact with immunosuppressant medications.
• Mild gastrointestinal upset (nausea, diarrhea, heartburn) is the most common side effect.
• Limited long-term healthspan-specific safety data.

Verdict

Effective for inflammation management; promising indirect healthspan benefits.